Tc 99m tilmanocept
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kaposi's Sarcoma
Conditions
Kaposi's Sarcoma
Trial Timeline
Sep 1, 2014 → Oct 1, 2015
NCT ID
NCT02201420About Tc 99m tilmanocept
Tc 99m tilmanocept is a phase 2 stage product being developed by Navidea Biopharmaceuticals for Kaposi's Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02201420. Target conditions include Kaposi's Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04078191 | Phase 2 | Terminated |
| NCT03938636 | Phase 2 | Completed |
| NCT02201420 | Phase 2 | Completed |
Competing Products
5 competing products in Kaposi's Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 41 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Merck | Approved | 85 |
| Maraviroc | Pfizer | Phase 2 | 51 |
| 50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin | ImmunityBio | Phase 2 | 49 |
| VEGF inhibitor PTC299 | PTC Therapeutics | Phase 1/2 | 38 |